Knockdown of lncRNA SSTR5-AS1 Regulates Ferroptosis and Immunosuppressive Factor Expression Through STAT3/SLC7A11 Signaling Pathway to Interfere with the Progression of Ovarian Cancer
-
Qiong Wei
,
Chun Wang
,
Yi Yang
,
Yuping Li
,
Huan Huang
Abstract
Long noncoding RNA SSTR5 antisense RNA 1 (lncRNA SSTR5-AS1) is increased in a variety of tumors, but its molecular mechanism in ovarian cancer (OC) remains unreported.
lncRNA SSTR5-AS1 and signal transducer and activator of transcription 3 (STAT3) expressions in SKOV3 and A2780 cells were interfered (n=3), and the cells were treated with ferroptosis inhibitor Ferrostatin-1. lncRNA SSTR5-AS1 and STAT3 expressions were discovered. The interaction between them was detected by immunoprecipitation assay. The cell malignant progression was evaluated through Transwell and scratch healing assays. Ferroptosis was measured through kits and fluorescent probes; the expression levels of immunosuppressive factors and STAT3/solute carrier family 7 member 11 (SLC7A11) signaling pathway were discovered through Western blot. A transplanted tumor model (n=6 mice per group) was established to evaluate ferroptosis, immunosuppressive factors, and tumor growth in tumor tissues.
lncRNA SSTR5-AS1 was up-regulated on OC cells. LncRNA SSTR5-AS1 and STAT3 bind to each other, and knockdown of lncRNA SSTR5-AS1 can reduce p-STAT3/STAT3 and SLC7A11 protein levels (one-way ANOVA). Knocking down lncRNA SSTR5-AS1 and STAT3 suppressed cell viability, migratory rate, and invasive cell number; increased reactive oxygen species (ROS) and Fe2+ levels; and reduced immunosuppressive factors and ferroptosis proteins. Ferrostatin-1 significantly reversed the effect of knockdown of lncRNA SSTR5-AS1 on ferroptosis. In transplanted tumor tissues, downregulation of lncRNA SSTR5-AS1 can reduce tumor size and volume, show obvious iron deposition, and reduce the secretion of immunosuppressive factors.
Knockdown of lncRNA SSTR5-AS1 induces ferroptosis and reduces the secretion of immunosuppressive factors through the STAT3/SLC7A11 pathway, thereby antagonizing OC.
1. Pal S, Bhowmick S, Sharma A, Sierra-Fonseca JA, Mondal S, Afolabi F, et al. Lymphatic vasculature in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2023;1878(5):188950.
2. Wang X, Zhou Y, Zhou X, Zhang B, Liang H, Chen Y. tsRNA-Ala-3-0030 drives ovarian cancer progression by suppressing ZNF70. Front Oncol. 2026;29:1738006.
3. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J National Cancer Center. 2024;4(1):47-53.
4. Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, et al. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022;139(2):157-62.
5. Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, et al. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells. 2022;11(4): 650.
6. Ogasawara A, Sato S, Hasegawa K. Current and future strategies for treatment of ovarian clear cell carcinoma. J Obstet Gynaecol Res. 2020;46(9):1678-89.
7. Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239-57.
8. Yapici FI, Bebber CM, von Karstedt S. A guide to ferroptosis in cancer. Mol Oncol. 2024;18(6):1378-96.
9. Singh M, Arora HL, Naik R, Joshi S, Sonawane K, Sharma NK, et al. Ferroptosis in Cancer: Mechanism and Therapeutic Potential. Int J Mol Sci. 2025;26(8):3852.
10. Su C, Xue Y, Fan S, Sun X, Si Q, Gu Z, et al. Ferroptosis and its relationship with cancer. Front Cell Developmental Biol. 2024;12:1423869.
11. Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, et al. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis. Cancer Res. 2023;83(2):251-63.
12. Chen B, Zhao L, Yang R, Xu T. The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer. Front Genet. 2023;9(14):1275154.
13. Cang W, Wu A, Gu L, Wang W, Tian Q, Zheng Z, et al. Erastin enhances metastatic potential of ferroptosis-resistant ovarian cancer cells by M2 polarization through STAT3/IL-8 axis. Int Immunopharmacol. 2022;113(Pt B):109422.
14. Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88-116.
15. Zhao H, Xu Y, Shang H. Ferroptosis: A New Promising Target for Ovarian Cancer Therapy. Int J Med Sci. 2022;19(13):1847-55.
16. Yuan Y, Tang Y, Fang Z, Wen J, Wicha MS, Luo M. Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness. Cells. 2025;14(3):227.
17. Li J, Wang X, Wang H. RNA modifications in long non-coding RNAs and their implications in cancer biology. Bioorg Med Chem. 2024;113(8):117922.
18. Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Gen. 2024;25(8):578-95.
19. Lin H, Xu X, Chen K, Fu Z, Wang S, Chen Y, et al. LncRNA CASC15, MiR-23b Cluster and SMAD3 form a Novel Positive Feedback Loop to promote Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer. Int J Biol Sci. 2022;18(5):1989-2002.
20. Basu S, Nadhan R, Dhanasekaran DN. Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications. Cancers. 2025;17(3):472.
21. Xue Z, Yang B, Xu Q, Zhu X, Qin G. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma. Biochem Biophys Res Commun. 2020;522(4):952-9.
22. Hu Y, Mao N, Zheng W, Hong B, Deng X. lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer. Dis Markers. 2023;2023:5025868.
23. Tang Z, Jiang Y, Zong Y, Ding S, Wu C, Tang Z, et al. LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling. Epigenomics. 2024;16(17):1133-48.
24. Yuan S, Bi J, Zhang Y. LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer. Crit Rev Eukaryot Gene Expr. 2023;33(2):1-12.
25. Cheng Y, Di J, Wu J, Shi HT, Zou BC, Zhang Y, et al. Diagnostic and prognostic significance of long noncoding RNA SSTR5-AS1 in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(10):5385-90.
26. Yang XC, Jin YJ, Ning R, Mao QY, Zhang PY, Zhou L, et al. Electroacupuncture attenuates ferroptosis by promoting Nrf2 nuclear translocation and activating Nrf2/SLC7A11/GPX4 pathway in ischemic stroke. Chinese Med. 2025;20(1):4.
27. Wang M, Zheng HS, Ye WL, Mao JD, Zhang K, Yang L, et al. The mechanism of electroacupuncture-mediated improvement in Parkinson's disease by inhibiting ferroptosis through activating the Nrf2/GPX4 signal pathway. Front Aging Neurosci. 2025;17:1551404.
28. Chen L, Sun R, Fang K. Erianin inhibits tumor growth by promoting ferroptosis and inhibiting invasion in hepatocellular carcinoma through the JAK2/STAT3/SLC7A11 pathway. Pathol Int. 2024;74(3):119-28.
29. Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.
30. Liu K, Huang A, Nie J, Tan J, Xing S, Qu Y, et al. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Front Immunol. 2021;12:683332.
31. Martincuks A, Song J, Kohut A, Zhang C, Li YJ, Zhao Q, et al. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer. Front Oncol. 2021;11:724104.
32. Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317.
33. Yang R, Gao W, Wang Z, Jian H, Peng L, Yu X, et al. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine
. 2024;122:155135.
34. Zhang R, Zhang L, Fan S, Wang L, Wang B, Wang L. Squalene monooxygenase (SQLE) protects ovarian cancer cells from ferroptosis. Sci Reports. 2024;14(1):22646.
35. Zhao Y, Liang H, Cui X. Obacunone regulates ferroptosis in ovarian cancer through the Akt/p53 pathway. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(6):7027-39.
36. Liu D, Zhu Y. Unveiling Smyd-2's Role in Cytoplasmic Nrf-2 Sequestration and Ferroptosis Induction in Hippocampal Neurons After Cerebral Ischemia/Reperfusion. Cells. 2024;13(23):1969.
37. Yao D, Bao L, Wang S, Tan M, Xu Y, Wu T, et al. Isoliquiritigenin alleviates myocardial ischemia-reperfusion injury by regulating the Nrf2/HO-1/SLC7a11/GPX4 axis in mice. Free Radic Biol Med. 2024;221:1-12.
38. Xu Y, Chen J, Zhou L, Zhao Y, He N, Xu Q, et al. Gastrodin Protects Against Sepsis-Associated Encephalopathy By Suppressing Ferroptosis. Shock (Augusta, Ga). 2025;63(4):628-37.
39. Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;152:175-85.
40. Zhou TJ, Zhang MM, Liu DM, Huang LL, Yu HQ, Wang Y, et al. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer. Biomaterials. 2024;305:122447.
41. Wang K, Mei S, Cai M, Zhai D, Zhang D, Yu J, et al. Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer. Front Oncol. 2022;12:888699.
42. Zheng J, Guo J, Wang Y, Zheng Y, Zhang K, Tong J. Bioinformatic Analyses of the Ferroptosis-Related lncRNAs Signature for Ovarian Cancer. Front Mol Biosciences. 2021;8:735871.
43. Li S, Tao K, Yun H, Yang J, Meng Y, Zhang F, et al. Ferroptosis is a protective factor for the prognosis of cancer patients: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):604.
44. Han S, Wang S, Lv X, Li D, Feng Y. Ferroptosis-related genes in cervical cancer as biomarkers for predicting the prognosis of gynecological tumors. Front Mol Biosciences. 2023;10:1188027.
45. Fantone S, Piani F, Olivieri F, Rippo MR, Sirico A, Di Simone N, et al. Role of SLC7A11/xCT in Ovarian Cancer. Int J Mol Sci. 2024;25(1):587.
46. Wu H, Liao X, Huang W, Hu H, Lan L, Yang Q, et al. Examining the prognostic and clinicopathological significance of GPX4 in human cancers: a meta-analysis. Free Radic Res. 2025;59(3):239-49.
47. Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, et al. STAT3 signaling in ovarian cancer: a potential therapeutic target. J Cancer. 2020;11(4):837-48.
48. Li Q, Yang F, Shi X, Bian S, Shen F, Wu Y, et al. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway. FEBS Open Bio. 2021;11(10):2845-57.
49. Wu K, Qiu C, Ma Q, Chen F, Lu T. The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer. Toxicol Applied Pharmacol. 2024;491:117077.
50. Wu K, Liu L, Wu Z, Huang Q, Zhou L, Xie R, et al. Ascorbic acid induces ferroptosis via STAT3/GPX4 signaling in oropharyngeal cancer. Free Radic Res. 2024;58(2):117-29.
51. Huang CY, Chen LJ, Chen G, Chao TI, Wang CY. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. Int J Mol Sci. 2022;23(19):11092.
52. Mo M, Pan L, Deng L, Liang M, Xia N, Liang Y. Iron Overload Induces Hepatic Ferroptosis and Insulin Resistance by Inhibiting the Jak2/stat3/slc7a11 Signaling Pathway. Cell Biochemistry Biophysics. 2024;82(3):2079-94.
53. Yang K, Zhang X, Long F, Dai J. AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11. Cell Biol Int. 2025;49(4):374-83.
54. Luo Y, Gao X, Zou L, Lei M, Feng J, Hu Z. Bavachin Induces Ferroptosis through the STAT3/P53/SLC7A11 Axis in Osteosarcoma Cells. Oxid Med Cell Longev. 2021;2021:1783485.
2. Wang X, Zhou Y, Zhou X, Zhang B, Liang H, Chen Y. tsRNA-Ala-3-0030 drives ovarian cancer progression by suppressing ZNF70. Front Oncol. 2026;29:1738006.
3. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J National Cancer Center. 2024;4(1):47-53.
4. Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, et al. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022;139(2):157-62.
5. Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, et al. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells. 2022;11(4): 650.
6. Ogasawara A, Sato S, Hasegawa K. Current and future strategies for treatment of ovarian clear cell carcinoma. J Obstet Gynaecol Res. 2020;46(9):1678-89.
7. Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239-57.
8. Yapici FI, Bebber CM, von Karstedt S. A guide to ferroptosis in cancer. Mol Oncol. 2024;18(6):1378-96.
9. Singh M, Arora HL, Naik R, Joshi S, Sonawane K, Sharma NK, et al. Ferroptosis in Cancer: Mechanism and Therapeutic Potential. Int J Mol Sci. 2025;26(8):3852.
10. Su C, Xue Y, Fan S, Sun X, Si Q, Gu Z, et al. Ferroptosis and its relationship with cancer. Front Cell Developmental Biol. 2024;12:1423869.
11. Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, et al. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis. Cancer Res. 2023;83(2):251-63.
12. Chen B, Zhao L, Yang R, Xu T. The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer. Front Genet. 2023;9(14):1275154.
13. Cang W, Wu A, Gu L, Wang W, Tian Q, Zheng Z, et al. Erastin enhances metastatic potential of ferroptosis-resistant ovarian cancer cells by M2 polarization through STAT3/IL-8 axis. Int Immunopharmacol. 2022;113(Pt B):109422.
14. Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88-116.
15. Zhao H, Xu Y, Shang H. Ferroptosis: A New Promising Target for Ovarian Cancer Therapy. Int J Med Sci. 2022;19(13):1847-55.
16. Yuan Y, Tang Y, Fang Z, Wen J, Wicha MS, Luo M. Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness. Cells. 2025;14(3):227.
17. Li J, Wang X, Wang H. RNA modifications in long non-coding RNAs and their implications in cancer biology. Bioorg Med Chem. 2024;113(8):117922.
18. Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Gen. 2024;25(8):578-95.
19. Lin H, Xu X, Chen K, Fu Z, Wang S, Chen Y, et al. LncRNA CASC15, MiR-23b Cluster and SMAD3 form a Novel Positive Feedback Loop to promote Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer. Int J Biol Sci. 2022;18(5):1989-2002.
20. Basu S, Nadhan R, Dhanasekaran DN. Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications. Cancers. 2025;17(3):472.
21. Xue Z, Yang B, Xu Q, Zhu X, Qin G. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma. Biochem Biophys Res Commun. 2020;522(4):952-9.
22. Hu Y, Mao N, Zheng W, Hong B, Deng X. lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer. Dis Markers. 2023;2023:5025868.
23. Tang Z, Jiang Y, Zong Y, Ding S, Wu C, Tang Z, et al. LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling. Epigenomics. 2024;16(17):1133-48.
24. Yuan S, Bi J, Zhang Y. LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer. Crit Rev Eukaryot Gene Expr. 2023;33(2):1-12.
25. Cheng Y, Di J, Wu J, Shi HT, Zou BC, Zhang Y, et al. Diagnostic and prognostic significance of long noncoding RNA SSTR5-AS1 in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(10):5385-90.
26. Yang XC, Jin YJ, Ning R, Mao QY, Zhang PY, Zhou L, et al. Electroacupuncture attenuates ferroptosis by promoting Nrf2 nuclear translocation and activating Nrf2/SLC7A11/GPX4 pathway in ischemic stroke. Chinese Med. 2025;20(1):4.
27. Wang M, Zheng HS, Ye WL, Mao JD, Zhang K, Yang L, et al. The mechanism of electroacupuncture-mediated improvement in Parkinson's disease by inhibiting ferroptosis through activating the Nrf2/GPX4 signal pathway. Front Aging Neurosci. 2025;17:1551404.
28. Chen L, Sun R, Fang K. Erianin inhibits tumor growth by promoting ferroptosis and inhibiting invasion in hepatocellular carcinoma through the JAK2/STAT3/SLC7A11 pathway. Pathol Int. 2024;74(3):119-28.
29. Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.
30. Liu K, Huang A, Nie J, Tan J, Xing S, Qu Y, et al. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Front Immunol. 2021;12:683332.
31. Martincuks A, Song J, Kohut A, Zhang C, Li YJ, Zhao Q, et al. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer. Front Oncol. 2021;11:724104.
32. Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317.
33. Yang R, Gao W, Wang Z, Jian H, Peng L, Yu X, et al. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine
. 2024;122:155135.
34. Zhang R, Zhang L, Fan S, Wang L, Wang B, Wang L. Squalene monooxygenase (SQLE) protects ovarian cancer cells from ferroptosis. Sci Reports. 2024;14(1):22646.
35. Zhao Y, Liang H, Cui X. Obacunone regulates ferroptosis in ovarian cancer through the Akt/p53 pathway. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(6):7027-39.
36. Liu D, Zhu Y. Unveiling Smyd-2's Role in Cytoplasmic Nrf-2 Sequestration and Ferroptosis Induction in Hippocampal Neurons After Cerebral Ischemia/Reperfusion. Cells. 2024;13(23):1969.
37. Yao D, Bao L, Wang S, Tan M, Xu Y, Wu T, et al. Isoliquiritigenin alleviates myocardial ischemia-reperfusion injury by regulating the Nrf2/HO-1/SLC7a11/GPX4 axis in mice. Free Radic Biol Med. 2024;221:1-12.
38. Xu Y, Chen J, Zhou L, Zhao Y, He N, Xu Q, et al. Gastrodin Protects Against Sepsis-Associated Encephalopathy By Suppressing Ferroptosis. Shock (Augusta, Ga). 2025;63(4):628-37.
39. Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;152:175-85.
40. Zhou TJ, Zhang MM, Liu DM, Huang LL, Yu HQ, Wang Y, et al. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer. Biomaterials. 2024;305:122447.
41. Wang K, Mei S, Cai M, Zhai D, Zhang D, Yu J, et al. Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer. Front Oncol. 2022;12:888699.
42. Zheng J, Guo J, Wang Y, Zheng Y, Zhang K, Tong J. Bioinformatic Analyses of the Ferroptosis-Related lncRNAs Signature for Ovarian Cancer. Front Mol Biosciences. 2021;8:735871.
43. Li S, Tao K, Yun H, Yang J, Meng Y, Zhang F, et al. Ferroptosis is a protective factor for the prognosis of cancer patients: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):604.
44. Han S, Wang S, Lv X, Li D, Feng Y. Ferroptosis-related genes in cervical cancer as biomarkers for predicting the prognosis of gynecological tumors. Front Mol Biosciences. 2023;10:1188027.
45. Fantone S, Piani F, Olivieri F, Rippo MR, Sirico A, Di Simone N, et al. Role of SLC7A11/xCT in Ovarian Cancer. Int J Mol Sci. 2024;25(1):587.
46. Wu H, Liao X, Huang W, Hu H, Lan L, Yang Q, et al. Examining the prognostic and clinicopathological significance of GPX4 in human cancers: a meta-analysis. Free Radic Res. 2025;59(3):239-49.
47. Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, et al. STAT3 signaling in ovarian cancer: a potential therapeutic target. J Cancer. 2020;11(4):837-48.
48. Li Q, Yang F, Shi X, Bian S, Shen F, Wu Y, et al. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway. FEBS Open Bio. 2021;11(10):2845-57.
49. Wu K, Qiu C, Ma Q, Chen F, Lu T. The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer. Toxicol Applied Pharmacol. 2024;491:117077.
50. Wu K, Liu L, Wu Z, Huang Q, Zhou L, Xie R, et al. Ascorbic acid induces ferroptosis via STAT3/GPX4 signaling in oropharyngeal cancer. Free Radic Res. 2024;58(2):117-29.
51. Huang CY, Chen LJ, Chen G, Chao TI, Wang CY. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. Int J Mol Sci. 2022;23(19):11092.
52. Mo M, Pan L, Deng L, Liang M, Xia N, Liang Y. Iron Overload Induces Hepatic Ferroptosis and Insulin Resistance by Inhibiting the Jak2/stat3/slc7a11 Signaling Pathway. Cell Biochemistry Biophysics. 2024;82(3):2079-94.
53. Yang K, Zhang X, Long F, Dai J. AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11. Cell Biol Int. 2025;49(4):374-83.
54. Luo Y, Gao X, Zou L, Lei M, Feng J, Hu Z. Bavachin Induces Ferroptosis through the STAT3/P53/SLC7A11 Axis in Osteosarcoma Cells. Oxid Med Cell Longev. 2021;2021:1783485.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Ferroptosis Immunosuppression Long non-coding RNA SSTR5-AS1 Ovarian neoplasms SLC7A11 protein STAT3 transcription factor | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Wei Q, Wang C, Yang Y, Li Y, Huang H. Knockdown of lncRNA SSTR5-AS1 Regulates Ferroptosis and Immunosuppressive Factor Expression Through STAT3/SLC7A11 Signaling Pathway to Interfere with the Progression of Ovarian Cancer. Iran J Allergy Asthma Immunol. 2026;:1-21.
